Archives

img-01

China Medical Device Regulations: A 2025 Update

China Medical Device Regulatory Landscape: A 2025 Update Over the last year, there have been significant changes to China’s medical device regulatory environment as the government tries to strengthen regulatory oversight and improve market access for innovative products. The National Medical Products... Read More

img-01

China Drug Market Access Update (August 2025)

On July 10, China promulgated its 2025 National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalogue Adjustment Work Plan. This is an upgrade over the 2024 Basic Medical Insurance Scheme. The main component is the formal introduction of the Commercial... Read More

img-01

Quick Asia Drug Updates (August 2025)

Historically known for their strength in generic drug manufacturing, today, Indian pharma firms are increasing their in-licensing transactions with international drug innovators. Big Indian pharma firms such as Cipla, Sun Pharma, and Dr. Reddy’s are acquiring rights to new patented products in the oncology, diabetes, central... Read More

img-01

More Unannounced FDA Inspections in China and India

On May 6, 2025, the U.S. Food and Drug Administration (FDA) announced a substantial increase in unannounced inspections at foreign manufacturing facilities that manufacture medical products for U.S. import. This initiative is a result of a White House Executive Order directing agencies... Read More

img-01

China Medical Device Update

On May 13, China’s NMPA promulgated a new list of medical devices exempt from clinical trials. This new list, an update to the 2023 list, identifies 27 medical devices, including seven Class 3 products and 20 Class 2 products. In total, 1047 medical... Read More